Hannah E. Goulart

Internal Medicine

17 E 102nd St
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Evolving Paradigms in the Treatment of Philadelphia Chromosome-Positive ALL.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 08, 2026

Molecular Pathology of Myeloid Neoplasms.

Molecular Pathology of Myeloid Neoplasms.

Journal: Surgical pathology clinics

Published: May 06, 2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: April 12, 2026

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

Journal: Expert review of clinical pharmacology

Published: April 08, 2026

Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

Journal: American journal of hematology

Published: January 07, 2026

Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.

Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.

Journal: Blood advances

Published: January 02, 2026

Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.

Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.

Journal: Blood advances

Published: January 02, 2026

SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia.

SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 29, 2025

A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia-Positive Acute Lymphoblastic Leukemia.

A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia-Positive Acute Lymphoblastic Leukemia.

Journal: Acta haematologica

Published: December 23, 2025

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Journal: JCO precision oncology

Published: December 10, 2025

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

Journal: American journal of hematology

Published: November 25, 2025

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens.

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens.

Journal: American journal of hematology

Published: May 31, 2025

Showing 1-12 of 24

Last Updated: 09/26/2026